



Celgene Corporation
 Investor Relations Department
 86 Morris Avenue
 Summit, NJ 07901
 United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	88.95
Trade Time:	4:00 PM ET Apr 20, 2018
Change:	-0.67 (0.748%)
Day Range	88.25 - 90.13
52-Week Range	84.25 - 147.17
Volume	6,231,642

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Apr 19, 2018 [Celgene Corporation Announces Changes to Its Board of Directors](#)
- Apr 17, 2018 [Celgene Corporation to Webcast at Upcoming Investor Conferences](#)
- Apr 9, 2018 [Celgene Corporation to Announce First Quarter 2018 Results on May 04, 2018](#)
- Apr 2, 2018 [Celgene Corporation Announces Departure of President and Chief Operating Officer Scott A. Smith](#)
- Mar 28, 2018 [bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States](#)

Upcoming Events [\[View all \]](#)

- May 4, 2018 9:00 AM ET [Celgene Corporation Q1 2018 Earnings Conference Call](#)

Events [\[View all \]](#)

Financials [\[View all \]](#)

- Feb 7, 2018 [Annual Report \(10-K\)](#)
- Apr 27, 2017 [Proxy Statement \(DEF 14A\)](#)
- Oct 26, 2017 [Quarterly Report \(10-Q\)](#)
- Jul 27, 2017 [Quarterly Report \(10-Q\)](#)
- Apr 27, 2017 [Quarterly Report \(10-Q\)](#)